At ASHG, Illumina launches 5-base and shows exciting results from constellation, a breakthrough technology offering ...

The global next-generation sequencing market size is anticipated to reach USD 42.25 billion by 2033, growing at a CAGR of ...

By procedure type, the preimplantation genetic testing market is divided by procedure type into preimplantation genetic ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

Founded by former Illumina, Grail and Google leaders, Hepta is applying the technological, genomic and commercialization expertise that made liquid biopsy possible in oncology to the far larger field ...

Key opportunities in the precision oncology market include the rising adoption of personalized therapies, growth in ...

This article introduces the field of bioinformatics and its importance as a cornerstone of biological research, as well as ...

Request To Download Free Sample of This Strategic Report @ Market Overview: The global immuno-oncology assay market was valued at $2,769.50 million in 2018, and it is projected to reach $6,179.20 ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass USD 15.62 billion by 2030, growing at a CAGR of 12.42% ...

Introduction The aetiology of eating disorders (EDs) is complex, involving an interplay of genetic and environmental factors.

Recognizing the growing importance of insights from large genomic datasets, Illumina recently launched BioInsight to leverage sequencing, data analysis, software, and AI. You can learn more about ...

Simply put, Illumina tends to have better profitability ratios compared to its peers. For instance, Illumina has a 68.38% ...